About mepolizumab
Interleukin-5 (IL-5) monoclonal antibody
Used for
- Add-on maintenance treatment for severe eosinophilic asthma
- Add-on treatment for chronic rhinosinusitis with nasal polyps
- Treatment of eosinophilic granulomatosis with polyangiitis
- Treatment of hypereosinophilic syndrome
Usual adult dose
Asthma, nasal polyps, or EGPA: 100 mg under the skin every 4 weeks. HES: 300 mg every 4 weeks.
Usual dose in children
Asthma: ages 6–11, 40 mg under the skin every 4 weeks; ages 12 and older, 100 mg every 4 weeks. Other uses have age-specific limits.
Common side effects
- Headache
- Injection-site reactions
- Back pain
- Fatigue
Important warnings
- Not for sudden asthma attacks or acute breathing problems
- Serious allergic reactions, including anaphylaxis, can occur
- Treat existing parasitic worm infections before starting
- Do not abruptly stop inhaled or oral corticosteroids
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether mepolizumab passes into human milk; discuss potential benefits and risks.
Interactions
- No specific clinically significant drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.